NovaBay Pharmaceuticals, Inc. (NBY): Price and Financial Metrics


NovaBay Pharmaceuticals, Inc. (NBY): $2.07

-0.06 (-2.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NBY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NBY Stock Summary

  • NOVABAY PHARMACEUTICALS INC's market capitalization of $4,252,095 is ahead of only 0.64% of US-listed equities.
  • With a year-over-year growth in debt of 1,001.02%, NOVABAY PHARMACEUTICALS INC's debt growth rate surpasses 97.83% of about US stocks.
  • In terms of volatility of its share price, NBY is more volatile than 99.96% of stocks we're observing.
  • Stocks that are quantitatively similar to NBY, based on their financial statements, market capitalization, and price volatility, are ENG, CVCO, UTI, ZUMZ, and KRT.
  • NBY's SEC filings can be seen here. And to visit NOVABAY PHARMACEUTICALS INC's official web site, go to www.novabay.com.

NBY Valuation Summary

  • In comparison to the median Healthcare stock, NBY's price/sales ratio is 85% lower, now standing at 0.3.
  • NBY's price/sales ratio has moved down 16.8 over the prior 184 months.

Below are key valuation metrics over time for NBY.

Stock Date P/S P/B P/E EV/EBIT
NBY 2022-11-25 0.3 0.3 -0.5 -1.0
NBY 2022-11-23 0.4 0.3 -0.5 -1.1
NBY 2022-11-22 0.4 0.3 -0.5 -1.0
NBY 2022-11-21 0.3 0.3 -0.5 -1.0
NBY 2022-11-18 0.3 0.3 -0.4 -0.9
NBY 2022-11-17 0.3 0.3 -0.4 -0.9

NBY Growth Metrics

    The 2 year revenue growth rate now stands at 32.04%.
  • Its 4 year net income to common stockholders growth rate is now at 40.08%.
  • Its 5 year cash and equivalents growth rate is now at -39.99%.
Over the past 70 months, NBY's revenue has gone up $244,000.

The table below shows NBY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 12.141 -9.763 -8.952
2022-06-30 10.155 -9.542 -5.448
2022-03-31 9.243 -9.83 -5.152
2021-12-31 8.421 -9.192 -6.559
2021-09-30 7.668 -6.319 -7.42
2021-06-30 7.998 -6.221 -8.352

NBY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBY has a Quality Grade of C, ranking ahead of 44.35% of graded US stocks.
  • NBY's asset turnover comes in at 0.533 -- ranking 79th of 680 Pharmaceutical Products stocks.
  • AMGN, AMRN, and UTHR are the stocks whose asset turnover ratios are most correlated with NBY.

The table below shows NBY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.533 0.698 -7.529
2021-03-31 0.660 0.610 -9.044
2020-12-31 0.722 0.600 -7.838
2020-09-30 0.764 0.615 -6.542
2020-06-30 0.757 0.607 -3.607
2020-03-31 0.620 0.717 -1.768

NBY Stock Price Chart Interactive Chart >

Price chart for NBY

NBY Price/Volume Stats

Current price $2.07 52-week high $20.65
Prev. close $2.13 52-week low $2.00
Day low $2.04 Volume 48,600
Day high $2.15 Avg. volume 27,657
50-day MA $3.24 Dividend yield N/A
200-day MA $7.26 Market Cap 3.85M

NovaBay Pharmaceuticals, Inc. (NBY) Company Bio


NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products for the eye care market in the United States. The company was founded in 2000 and is based in Emeryville, California.


NBY Latest News Stream


Event/Time News Detail
Loading, please wait...

NBY Latest Social Stream


Loading social stream, please wait...

View Full NBY Social Stream

Latest NBY News From Around the Web

Below are the latest news stories about NOVABAY PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NBY as an investment opportunity.

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor’s Eczema Balm

EMERYVILLE, Calif., November 17, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network. Dr. Kunin will discuss DERMAdoctor’s moisturizing Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on "Give Gorgeous – Gifts With Purchase" hosted by two

Yahoo | November 17, 2022

NovaBay Pharmaceuticals Reports Third Quarter 2022 Financial Results

EMERYVILLE, Calif., November 14, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business update. Financial results for the first nine months of 2022 include DERMAdoctor, which NovaBay acquired on November 5, 2021.

Yahoo | November 14, 2022

NovaBay Pharmaceuticals Announces 1-for-35 Reverse Stock Split

EMERYVILLE, Calif., November 14, 2022--NovaBay® Pharmaceuticals, Inc. (the "Company") (NYSE American: NBY) announces that today, following approval from the Company’s stockholders obtained at the Company’s November 10, 2022 special stockholders’ meeting, the Company’s Board of Directors (the "Board") has approved the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a 1-for-35 reverse stock split of all outstanding shares of common s

Yahoo | November 14, 2022

NovaBay Pharmaceuticals to Hold Third Quarter 2022 Conference Call on November 14

EMERYVILLE, Calif., November 09, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Yahoo | November 9, 2022

NovaBay Pharmaceuticals Announces Expansion of DERMAdoctor Picture Porefect Collection with Launch of 15% Niacinamide Pore Minimizing Serum

EMERYVILLE, Calif., October 26, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the newest addition to the DERMAdoctor® Picture Porefect® collection: 15% Niacinamide Pore Minimizing Serum. This new, high-potency formulation minimizes the size of visible facial pores while delivering free-radical-neutralizing antioxidants and collagen-supporting agents to reduce blackheads, skin discoloration, rough skin, acne, and oily or combination skin.

Yahoo | October 26, 2022

Read More 'NBY' Stories Here

NBY Price Returns

1-mo -43.62%
3-mo -74.45%
6-mo -73.24%
1-year -87.42%
3-year -90.22%
5-year -98.59%
YTD -84.30%
2021 -45.97%
2020 8.91%
2019 -16.88%
2018 -80.00%
2017 16.67%

Continue Researching NBY

Want to see what other sources are saying about NovaBay Pharmaceuticals Inc's financials and stock price? Try the links below:

NovaBay Pharmaceuticals Inc (NBY) Stock Price | Nasdaq
NovaBay Pharmaceuticals Inc (NBY) Stock Quote, History and News - Yahoo Finance
NovaBay Pharmaceuticals Inc (NBY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.966 seconds.